Latest News
In this Issue
Most Popular on DTE Site
- Poison in disguise 1
- Public Deprived System 2
- A treaty too many 1
- Chaos in the iron age 2
- Health ministry sets timeframe for keeping animals treated with antibiotics out of food chain
- Gujarat pollution board gets a makeover in efficiency 33
- It’s a demographic disaster
- Auroville’s alternative galaxy
- Stage set for GM crops
- So much to give
- Environment ministry wants to restore night traffic through Bandipur tiger reserve 52
- A green facade 44
- Diesel: when bad policy makes for toxic hell 38
- Gujarat pollution board gets a makeover in efficiency 33
- What’s good insulation? 30
- How vulnerable are India's nuclear power plants to disaster 28
- Grand distraction called river interlinking 28
- Eat at your own risk 27
- Green energy takes toll on green cover 26
- Temporary solution, permanent jam 25
On Facebook
Crosscurrents
Cipla's bitter pill for MNCs
0 Comments
Issue Date: Jul 31, 2001
Several eyebrows have been raised over the Cipla offer to supply anti- aids drugs at one-third the current price to developing countries like South Africa. On March 7, 2001 Cipla Ltd of Mumbai, formally requested the South African department of trade and industry to issue compulsory licenses to patents on hiv drugs such as nevirapine, lamivudine, zidovudine, stavudine, didanosine, efavirenz, indinavir and abacavir.
No alternate text on picture! - define alternate text in image properties
Tags: Crosscurrents, Adis, Asia, Developing Countries, Development, Drug Industry, Drugs, Health Effects, India, Industry, Multi Cooperation, Patents, Research, South Africa, Trade
O
P
E
N
DTE Must Read
Good job bringing this to light. People won't realise how huge the problem is and municipalities are woefully ill equipped to...
Agreed; mining can never be sustainable, but then how do you get the metals to make all the things you need in the course of...
Very good piece.